Home › Companies › LIGAND PHARMACEUTICALS INC. › 2023-2024

LIGAND PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and LIGAND PHARMACEUTICALS INC.’s Form 8-K, filed June 17, 2024 (Item 5.07 on EDGAR). Page generated October 14, 2026.

  • 11Reported items
  • 297Asset managers
  • 3,629Fund votes
  • June 14, 2024Meeting date

Results at a glance

Meeting of June 14, 2024: 11 items on LIGAND PHARMACEUTICALS INC.’s Form 8-K, filed June 17, 2024: 8 elected · 3 approved.

Material dissent

  • Elect Director: Jason M. Aryeh 79% of votes cast Elected Director under 80%
  • 4. The approval of the Restated Plan 64% of votes cast Approved Under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore LIGAND PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by LIGAND PHARMACEUTICALS INC.

These tallies are LIGAND PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 17, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

LIGAND PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 14, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Jason M. Aryeh 12,265,786---- 3,259,8501,154,516 79%Elected—
Elect Director: Todd C. Davis 15,244,447---- 281,1891,154,516 98%Elected—
Elect Director: Nancy R. Gray, Ph.D. 14,876,443---- 649,1931,154,516 96%Elected—
Elect Director: Jason Haas 15,284,373---- 241,2631,154,516 98%Elected—
Elect Director: John W. Kozarich, Ph.D. 14,024,170---- 1,501,4661,154,516 90%Elected—
Elect Director: John L. LaMattina, Ph.D. 14,981,023---- 544,6131,154,516 96%Elected—
Elect Director: Stephen L. Sabba, M.D. 14,839,776---- 685,8601,154,516 96%Elected—
Elect Director: Martine Zimmermann, Pharm.D. 15,067,611---- 458,0251,154,516 97%Elected—
2. The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 15,908,245754,28517,622 ---- 95%Approved—
3. The approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers 14,264,2051,253,0858,346 --1,154,516 92%Approved—
4. The approval of the Restated Plan 9,926,6285,577,59021,418 --1,154,516 64%Approved—

Source: LIGAND PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 17, 2024 — read the filing on EDGAR.

How asset managers voted at the LIGAND PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 297 asset managers that disclosed a LIGAND PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of LIGAND PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Jason Haas

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 15,284,373WITHHELD: 241,263
Details: description as filed, official tally, votes by 89 asset managers

Description as filed by funds: Election of Directors: Jason Haas

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jason Haas”): 15,284,373 for, 241,263 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 9,494,058 for, 1,509 withheld, 1,150 abstained, 346 unknown.

FOR
FOR: 9,494,058ABSTAIN: 1,150WITHHOLD: 1,509UNKNOWN: 346
Largest asset managers voting on “Election of Directors: Jason Haas” at LIGAND PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,266,7550 00For
BlackRock1,643,5770 00For
JANUS INVESTMENT FUND912,4880 00For
Delaware/Macquarie737,6420 00For
Dimensional562,5950 00For
PROFESSIONALLY MANAGED PORTFOLIOS425,6580 00For
Fidelity341,0930 00For
State Street287,2970 049For
IMPAX FUNDS SERIES TRUST I255,2080 00For
DWS230,2180 00For
Charles Schwab143,2150 00For
BUFFALO FUNDS135,4820 00For
SEI107,5250 00For
Aberdeen104,2210 00For
Invesco103,2950 00For
Columbia Threadneedle98,5530 00For
Bridge Builder Trust93,9500 00For
OPTIMUM FUND TRUST70,6940 00For
Lincoln Financial66,4870 00For
Allspring66,4850 00For
WILLIAM BLAIR FUNDS60,3400 00For
Equitable47,0160 00For
AMERICAN BEACON FUNDS45,1940 00For
TIAA42,6650 00For
Jackson National39,2820 00For

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

2. Elect Director: Jason M. Aryeh

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD
FOR: 12,265,786WITHHELD: 3,259,850
Details: description as filed, official tally, votes by 89 asset managers

Description as filed by funds: Election of Directors: Jason M. Aryeh

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jason M. Aryeh”): 12,265,786 for, 3,259,850 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 7,821,461 for, 1,673,740 withheld, 1,516 abstained, 346 unknown.

FORWITHHOLD
FOR: 7,821,461ABSTAIN: 1,516WITHHOLD: 1,673,740UNKNOWN: 346
Largest asset managers voting on “Election of Directors: Jason M. Aryeh” at LIGAND PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,266,7550 00For
BlackRock1,643,5770 00For
JANUS INVESTMENT FUND912,4880 00For
Delaware/Macquarie00 0737,642Withhold
Dimensional562,5950 00For
PROFESSIONALLY MANAGED PORTFOLIOS425,6580 00For
Fidelity341,0930 00For
State Street5140 0286,832Withhold
IMPAX FUNDS SERIES TRUST I00 0255,208Withhold
DWS230,2180 00For
Charles Schwab143,2150 00For
BUFFALO FUNDS135,4820 00For
SEI00 0107,525Withhold
Aberdeen00 0104,221Withhold
Invesco103,2950 00For
Columbia Threadneedle98,5530 00For
Bridge Builder Trust93,6950 2550For
OPTIMUM FUND TRUST70,6940 00For
Lincoln Financial10,0310 056,456Mixed
Allspring66,4850 00For
WILLIAM BLAIR FUNDS60,3400 00For
Equitable47,0160 00For
AMERICAN BEACON FUNDS45,1940 00For
TIAA00 042,665Withhold
Jackson National39,2820 00For

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

3. Elect Director: John L. LaMattina, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 14,981,023WITHHELD: 544,613
Details: description as filed, official tally, votes by 89 asset managers

Description as filed by funds: Election of Directors: John L. LaMattina, Ph.D.

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: John L. LaMattina, Ph.D.”): 14,981,023 for, 544,613 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 9,493,169 for, 2,143 withheld, 1,405 abstained, 346 unknown.

FOR
FOR: 9,493,169ABSTAIN: 1,405WITHHOLD: 2,143UNKNOWN: 346
Largest asset managers voting on “Election of Directors: John L. LaMattina, Ph.D.” at LIGAND PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,266,7550 00For
BlackRock1,643,5770 00For
JANUS INVESTMENT FUND912,4880 00For
Delaware/Macquarie737,6420 00For
Dimensional562,5950 00For
PROFESSIONALLY MANAGED PORTFOLIOS425,6580 00For
Fidelity341,0930 00For
State Street287,2730 073For
IMPAX FUNDS SERIES TRUST I255,2080 00For
DWS230,2180 00For
Charles Schwab143,2150 00For
BUFFALO FUNDS135,4820 00For
SEI107,5250 00For
Aberdeen104,2210 00For
Invesco103,2950 00For
Columbia Threadneedle98,5530 00For
Bridge Builder Trust93,6950 2550For
OPTIMUM FUND TRUST70,6940 00For
Lincoln Financial66,4870 00For
Allspring66,4850 00For
WILLIAM BLAIR FUNDS60,3400 00For
Equitable47,0160 00For
AMERICAN BEACON FUNDS45,1940 00For
TIAA42,6650 00For
Jackson National39,2820 00For

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

4. Elect Director: John W. Kozarich, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 14,024,170WITHHELD: 1,501,466
Details: description as filed, official tally, votes by 89 asset managers

Description as filed by funds: Election of Directors: John W. Kozarich, Ph.D.

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: John W. Kozarich, Ph.D.”): 14,024,170 for, 1,501,466 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 9,099,749 for, 395,563 withheld, 1,405 abstained, 346 unknown.

FOR
FOR: 9,099,749ABSTAIN: 1,405WITHHOLD: 395,563UNKNOWN: 346
Largest asset managers voting on “Election of Directors: John W. Kozarich, Ph.D.” at LIGAND PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,266,7550 00For
BlackRock1,643,5770 00For
JANUS INVESTMENT FUND912,4880 00For
Delaware/Macquarie737,6420 00For
Dimensional562,5950 00For
PROFESSIONALLY MANAGED PORTFOLIOS425,6580 00For
Fidelity341,0930 00For
State Street287,2340 0112For
IMPAX FUNDS SERIES TRUST I00 0255,208Withhold
DWS230,2180 00For
Charles Schwab143,2150 00For
BUFFALO FUNDS135,4820 00For
SEI107,5250 00For
Aberdeen00 0104,221Withhold
Invesco103,2950 00For
Columbia Threadneedle98,5530 00For
Bridge Builder Trust93,6950 2550For
OPTIMUM FUND TRUST70,6940 00For
Lincoln Financial66,4870 00For
Allspring66,4850 00For
WILLIAM BLAIR FUNDS60,3400 00For
Equitable47,0160 00For
AMERICAN BEACON FUNDS45,1940 00For
TIAA42,6650 00For
Jackson National39,2820 00For

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

5. Elect Director: Martine Zimmermann, Pharm.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 15,067,611WITHHELD: 458,025
Details: description as filed, official tally, votes by 89 asset managers

Description as filed by funds: Election of Directors: Martine Zimmermann, Pharm.D.

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Martine Zimmermann, Pharm.D.”): 15,067,611 for, 458,025 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 9,470,183 for, 19,717 withheld, 1,150 abstained, 346 unknown.

FOR
FOR: 9,470,183ABSTAIN: 1,150WITHHOLD: 19,717UNKNOWN: 346
Largest asset managers voting on “Election of Directors: Martine Zimmermann, Pharm.D.” at LIGAND PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,266,7550 00For
BlackRock1,643,5770 00For
JANUS INVESTMENT FUND912,4880 00For
Delaware/Macquarie737,6420 00For
Dimensional562,5950 00For
PROFESSIONALLY MANAGED PORTFOLIOS425,6580 00For
Fidelity341,0930 00For
State Street287,3460 00For
IMPAX FUNDS SERIES TRUST I255,2080 00For
DWS230,2180 00For
Charles Schwab143,2150 00For
BUFFALO FUNDS135,4820 00For
SEI107,5250 00For
Aberdeen104,2210 00For
Invesco103,2950 00For
Columbia Threadneedle98,5530 00For
Bridge Builder Trust93,9500 00For
OPTIMUM FUND TRUST70,6940 00For
Lincoln Financial66,4870 00For
Allspring66,4850 00For
WILLIAM BLAIR FUNDS60,3400 00For
Equitable47,0160 00For
AMERICAN BEACON FUNDS45,1940 00For
TIAA42,6650 00For
Jackson National39,2820 00For

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

6. Elect Director: Nancy R. Gray, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 14,876,443WITHHELD: 649,193
Details: description as filed, official tally, votes by 89 asset managers

Description as filed by funds: Election of Directors: Nancy R. Gray, Ph.D.

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Nancy R. Gray, Ph.D.”): 14,876,443 for, 649,193 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 9,471,835 for, 23,477 withheld, 1,405 abstained, 346 unknown.

FOR
FOR: 9,471,835ABSTAIN: 1,405WITHHOLD: 23,477UNKNOWN: 346
Largest asset managers voting on “Election of Directors: Nancy R. Gray, Ph.D.” at LIGAND PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,266,7550 00For
BlackRock1,643,5770 00For
JANUS INVESTMENT FUND912,4880 00For
Delaware/Macquarie737,6420 00For
Dimensional562,5950 00For
PROFESSIONALLY MANAGED PORTFOLIOS425,6580 00For
Fidelity341,0930 00For
State Street287,2570 089For
IMPAX FUNDS SERIES TRUST I255,2080 00For
DWS230,2180 00For
Charles Schwab143,2150 00For
BUFFALO FUNDS135,4820 00For
SEI107,5250 00For
Aberdeen104,2210 00For
Invesco103,2950 00For
Columbia Threadneedle98,5530 00For
Bridge Builder Trust93,6950 2550For
OPTIMUM FUND TRUST70,6940 00For
Lincoln Financial66,4870 00For
Allspring66,4850 00For
WILLIAM BLAIR FUNDS60,3400 00For
Equitable47,0160 00For
AMERICAN BEACON FUNDS45,1940 00For
TIAA42,6650 00For
Jackson National39,2820 00For

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

7. Elect Director: Stephen L. Sabba, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 14,839,776WITHHELD: 685,860
Details: description as filed, official tally, votes by 89 asset managers

Description as filed by funds: Election of Directors: Stephen L. Sabba, M.D..

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Stephen L. Sabba, M.D.”): 14,839,776 for, 685,860 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 9,471,880 for, 23,432 withheld, 1,405 abstained, 346 unknown.

FOR
FOR: 9,471,880ABSTAIN: 1,405WITHHOLD: 23,432UNKNOWN: 346
Largest asset managers voting on “Election of Directors: Stephen L. Sabba, M.D..” at LIGAND PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,266,7550 00For
BlackRock1,643,5770 00For
JANUS INVESTMENT FUND912,4880 00For
Delaware/Macquarie737,6420 00For
Dimensional562,5950 00For
PROFESSIONALLY MANAGED PORTFOLIOS425,6580 00For
Fidelity341,0930 00For
State Street287,2730 073For
IMPAX FUNDS SERIES TRUST I255,2080 00For
DWS230,2180 00For
Charles Schwab143,2150 00For
BUFFALO FUNDS135,4820 00For
SEI107,5250 00For
Aberdeen104,2210 00For
Invesco103,2950 00For
Columbia Threadneedle98,5530 00For
Bridge Builder Trust93,6950 2550For
OPTIMUM FUND TRUST70,6940 00For
Lincoln Financial66,4870 00For
Allspring66,4850 00For
WILLIAM BLAIR FUNDS60,3400 00For
Equitable25,7270 021,289Mixed
AMERICAN BEACON FUNDS45,1940 00For
TIAA42,6650 00For
Jackson National39,2820 00For

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

8. Elect Director: Todd C. Davis

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 15,244,447WITHHELD: 281,189
Details: description as filed, official tally, votes by 89 asset managers

Description as filed by funds: Election of Directors: Todd C. Davis

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Todd C. Davis”): 15,244,447 for, 281,189 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 9,493,348 for, 1,964 withheld, 1,405 abstained, 346 unknown.

FOR
FOR: 9,493,348ABSTAIN: 1,405WITHHOLD: 1,964UNKNOWN: 346
Largest asset managers voting on “Election of Directors: Todd C. Davis” at LIGAND PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,266,7550 00For
BlackRock1,643,5770 00For
JANUS INVESTMENT FUND912,4880 00For
Delaware/Macquarie737,6420 00For
Dimensional562,5950 00For
PROFESSIONALLY MANAGED PORTFOLIOS425,6580 00For
Fidelity341,0930 00For
State Street287,2730 073For
IMPAX FUNDS SERIES TRUST I255,2080 00For
DWS230,2180 00For
Charles Schwab143,2150 00For
BUFFALO FUNDS135,4820 00For
SEI107,5250 00For
Aberdeen104,2210 00For
Invesco103,2950 00For
Columbia Threadneedle98,5530 00For
Bridge Builder Trust93,6950 2550For
OPTIMUM FUND TRUST70,6940 00For
Lincoln Financial66,4870 00For
Allspring66,4850 00For
WILLIAM BLAIR FUNDS60,3400 00For
Equitable47,0160 00For
AMERICAN BEACON FUNDS45,1940 00For
TIAA42,6650 00For
Jackson National39,2820 00For

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

9. Approval of an amendment and restatement of Ligand's 2002 Stock Incentive Plan

No official matchCOMPENSATION

Combines 5 wordings of this item as funds reported it.

66% of fund votes cast · no official result

FORAGAINST
Details: votes by 95 asset managers

The 95 asset managers below reported 6,270,582 for, 3,204,714 against, 15,443 abstained, 346 unknown. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 6,270,582AGAINST: 3,204,714ABSTAIN: 15,443UNKNOWN: 346
Largest asset managers voting on “Approval of an amendment and restatement of Ligand's 2002 Stock Incentive Plan” at LIGAND PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard1,940,794325,961 00Mixed
BlackRock1,643,5770 00For
JANUS INVESTMENT FUND912,4880 00For
Delaware/Macquarie0737,642 00Against
Dimensional0562,595 00Against
PROFESSIONALLY MANAGED PORTFOLIOS425,6580 00For
Fidelity341,0930 00For
State Street243287,103 00Against
IMPAX FUNDS SERIES TRUST I255,2080 00For
DWS0230,218 00Against
Charles Schwab143,2150 00For
BUFFALO FUNDS135,4820 00For
SEI107,5250 00For
Aberdeen0104,221 00Against
Invesco0103,295 00Against
Columbia Threadneedle098,553 00Against
Bridge Builder Trust6,39787,553 00Mixed
OPTIMUM FUND TRUST70,6940 00For
Lincoln Financial066,487 00Against
Allspring066,485 00Against
WILLIAM BLAIR FUNDS060,340 00Against
Equitable25,72721,289 00Mixed
AMERICAN BEACON FUNDS045,194 00Against
TIAA42,6650 00For
Jackson National039,282 00Against

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

10. 3. The approval of a non-binding advisory resolution regarding the compensation of the Company's named executive…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 10 wordings of this item as funds reported it.

92% Approved · of votes cast

FOR 92%
FOR: 14,264,205AGAINST: 1,253,085
Details: description as filed, official tally, votes by 296 asset managers

Description as filed by funds: Approval, on an advisory basis, of the compensation of the named executive officers

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“3. The approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers”): 14,264,205 for, 1,253,085 against — passed, per its Form 8-K filed June 17, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “In accordance with the results below, the proposal was approved.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 93 asset managers voting on “Approval, on an advisory basis, of the compensation of the named executive officers” at LIGAND PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,266,7550 00For
BlackRock1,643,5770 00For
JANUS INVESTMENT FUND912,4880 00For
Delaware/Macquarie737,6420 00For
Dimensional562,5950 00For
PROFESSIONALLY MANAGED PORTFOLIOS425,6580 00For
Fidelity341,0930 00For
State Street287,25789 00For
IMPAX FUNDS SERIES TRUST I255,2080 00For
DWS230,2180 00For
Charles Schwab143,2150 00For
BUFFALO FUNDS135,4820 00For
SEI107,5250 00For
Aberdeen0104,221 00Against
Invesco0103,295 00Against
Columbia Threadneedle098,553 00Against
Bridge Builder Trust93,9500 00For
OPTIMUM FUND TRUST70,6940 00For
Lincoln Financial66,4870 00For
Allspring66,4850 00For
WILLIAM BLAIR FUNDS60,3400 00For
Equitable47,0160 00For
AMERICAN BEACON FUNDS45,1940 00For
TIAA42,6650 00For
Jackson National39,2820 00For

Fund voting reports, all 93 managers: 9,140,585 for, 377,995 against, 1,460 abstained, 346 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 230 asset managers voting on “Approval, on an advisory basis, of the compensation of the named executive officers” at LIGAND PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Janus Henderson975,6010 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST883,7000 00For
State Street611,650249 00For
CONGRESS ASSET MANAGEMENT CO /MA514,4330 00For
Stephens Investment Management Group LLC508,0050 00For
Man Group plc0468,510 00Against
BlackRock416,3965,101 00For
VILLERE ST DENIS J & CO LLC417,3640 00For
GEODE CAPITAL MANAGEMENT, LLC356,6710 00For
Aberdeen0264,396 00Against
ASHFORD CAPITAL MANAGEMENT INC226,2850 00For
RICE HALL JAMES & ASSOCIATES, LLC3,402218,605 00Against
CARDINAL CAPITAL MANAGEMENT LLC /CT218,4210 00For
Northern Trust160,19311 00For
Charles Schwab151,8060 00For
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC140,8310 00For
SEI127,92211,667 00Mixed
Chicago Capital, LLC138,2330 00For
MELLON INVESTMENTS Corp118,1430 00For
Invesco0109,538 00Against
PRINCIPAL GLOBAL INVESTORS89,5260 00For
Knott David M Jr75,0000 00For
Allspring73,9910 00For
NORDEA INVESTMENT MANAGEMENT AB068,355 00Against
ENVESTNET ASSET MANAGEMENT INC65,9220 00For

Institutional-manager reports, all 230 managers: 7,512,667 for, 1,351,577 against, 284 abstained, 385 not voted, 1,448 unknown. Showing the 25 largest; see all in the interactive database.

11. 2. The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 15,908,245AGAINST: 754,285
Details: description as filed, official tally, votes by 94 asset managers

Description as filed by funds: Ratification of Ernst & Young LLP as Ligand's independent registered accounting firm

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“2. The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 15,908,245 for, 754,285 against — passed, per its Form 8-K filed June 17, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “In accordance with the results below, the selection of Ernst & Young LLP was ratified.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 9,490,329 for, 11,340 against, 1,460 abstained, 346 unknown.

FOR
FOR: 9,490,329AGAINST: 11,340ABSTAIN: 1,460UNKNOWN: 346
Largest asset managers voting on “Ratification of Ernst & Young LLP as Ligand's independent registered accounting firm” at LIGAND PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,266,7550 00For
BlackRock1,643,5770 00For
JANUS INVESTMENT FUND912,4880 00For
Delaware/Macquarie737,6420 00For
Dimensional562,5950 00For
PROFESSIONALLY MANAGED PORTFOLIOS425,6580 00For
Fidelity341,0930 00For
State Street287,32323 00For
IMPAX FUNDS SERIES TRUST I255,2080 00For
DWS230,2180 00For
Charles Schwab143,2150 00For
BUFFALO FUNDS135,4820 00For
SEI107,5250 00For
Aberdeen104,2210 00For
Invesco103,2950 00For
Columbia Threadneedle98,5530 00For
Bridge Builder Trust93,9500 00For
OPTIMUM FUND TRUST70,6940 00For
Lincoln Financial66,4870 00For
Allspring66,4850 00For
WILLIAM BLAIR FUNDS60,3400 00For
Equitable47,0160 00For
AMERICAN BEACON FUNDS45,1940 00For
TIAA42,6650 00For
Jackson National39,2820 00For

Showing the 25 largest of 94 asset managers. See all 94 in the interactive database.

Largest LIGAND PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 17,924,000 shares outstanding at the time of that meeting.

Fund voting reports: top LIGAND PHARMACEUTICALS INC. shareholders by shares voted on “Approval, on an advisory basis, of the compensation of the named executive officers”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 12.65%
2BlackRock 9.17%
3JANUS INVESTMENT FUND 5.09%
4Delaware/Macquarie 4.12%
5Dimensional 3.14%
6PROFESSIONALLY MANAGED PORTFOLIOS 2.37%
7Fidelity 1.90%
8State Street 1.60%
9IMPAX FUNDS SERIES TRUST I 1.42%
10DWS 1.28%
Institutional-manager reports: top LIGAND PHARMACEUTICALS INC. shareholders by shares voted on “Approval, on an advisory basis, of the compensation of the named executive officers”, 2023-2024
#Asset manager % of shares outstanding
1Janus Henderson 5.44%
2MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST 4.93%
3State Street 3.41%
4CONGRESS ASSET MANAGEMENT CO /MA 2.87%
5Stephens Investment Management Group LLC 2.83%
6Man Group plc 2.61%
7BlackRock 2.35%
8VILLERE ST DENIS J & CO LLC 2.33%
9GEODE CAPITAL MANAGEMENT, LLC 1.99%
10Aberdeen 1.48%

Reported LIGAND PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

LIGAND PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder % outstanding Disclosure
BlackRock 16.09% 13F
Vanguard Group 11.58% 13F
Janus Henderson Group plc 7.49% DEF14A
Macquarie Group Limited 5.51% DEF14A
State Street 3.75% 13F
Dimensional Fund Advisors 3.70% 13F
FMR (Fidelity) 2.55% 13F
Geode Capital 2.13% 13F
Goldman Sachs 2.05% 13F
Matthew Korenberg 1.36% DEF14A

Percentages above are of 17,924,000 shares outstanding, as reported by LIGAND PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from LIGAND PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At LIGAND PHARMACEUTICALS INC.'s shareholder meeting held June 14, 2024, in the 2023-2024 proxy season, 297 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,629 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory basis, of the compensation of the named executive officers — LIGAND PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: LIGAND PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 17, 2024.

LIGAND PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.